Druggability assessment asks whether a biological target contains features suitable for modulation by a drug-like molecule. For TNIK in idiopathic pulmonary fibrosis, the assessment predicted that its kinase domain could support small-molecule inhibition: the ATP-binding pocket offered a defined site, while sequence differences from other kinases suggested a path toward selectivity. section 13.3.1
TNIK as a target
TNIK combined substantial biological evidence with limited prior investigation: it participated in inflammatory and fibrotic signaling, genetic studies linked its locus to fibrotic disease, and IPF tissue showed increased expression. After analysis and expert review, it was selected despite lacking selective inhibitors or ligand-bound crystal structures. section 13.3.1
